Frank Hilberg

Frank Hilberg

UNVERIFIED PROFILE

Are you Frank Hilberg?   Register this Author

Register author
Frank Hilberg

Frank Hilberg

Publications by authors named "Frank Hilberg"

Are you Frank Hilberg?   Register this Author

22Publications

766Reads

48Profile Views

Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity.

Angiogenesis 2019 11 28;22(4):535-546. Epub 2019 Aug 28.

Department of Medical Biophysics, University of Toronto, Toronto, ON, M5S 2J7, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10456-019-09677-xDOI Listing
November 2019

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Future Oncol 2019 Apr 13;15(12):1363-1383. Epub 2019 Feb 13.

Boehringer Ingelheim Pharma GmbH & Co, KG, Germany & Institute of Pharmacology, Johannes Gutenberg-University Mainz, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0948DOI Listing
April 2019

Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.

Br J Cancer 2019 01 31;120(1):69-78. Epub 2018 Oct 31.

Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Center for Molecular Medicine Cologne (CMMC) and Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, CECAD Research Center, Joseph-Stelzmann-Str. 26, 50931, Cologne, Germany.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-018-0198-3
Publisher Site
http://dx.doi.org/10.1038/s41416-018-0198-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325148PMC
January 2019

Drug resistance profiles of mutations in the RET kinase domain.

Br J Pharmacol 2018 09 19;175(17):3504-3515. Epub 2018 Jul 19.

Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bph.14395DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086982PMC
September 2018

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.

J Pharmacol Exp Ther 2018 03 20;364(3):494-503. Epub 2017 Dec 20.

Boehringer Ingelheim RCV GmbH Co KG, Vienna, Austria (F.H., U.T.-G., A.B., S.L., D.G., T.V., P.G.-C., C.H., N.K.); University of Colorado, School of Medicine, Division of Medical Oncology, Aurora, Colorado (A.T.L., R.C.D.); and AstraZeneca - Innovative Medicines and Early Development, Discovery Sciences, Cambridge Science Park, Milton, Cambridge (D.G.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.117.244129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040086PMC
March 2018

BIBF1120 (Vargatef) Inhibits Preretinal Neovascularization and Enhances Normal Vascularization in a Model of Vasoproliferative Retinopathy.

Invest Ophthalmol Vis Sci 2015 Dec;56(13):7897-907

Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Center, Université de Montréal, Montréal, Quebec, Canada 2Department of Pediatrics, Ophthalmology and Pharmacology, Centre Hospitalier Universitaire Sainte-Justine Research Center, Univer.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1167/iovs.15-17146DOI Listing
December 2015

Nintedanib: from discovery to the clinic.

J Med Chem 2015 Feb 14;58(3):1053-63. Epub 2015 Jan 14.

Department of Medicinal Chemistry; §Department of Drug Metabolism and Pharmacokinetics; ‡Department of Non-Clinical Drug Safety; ∥Department of Translational Medicine and Clinical Pharmacology; ⊥Department of Respiratory Diseases Research; and #Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG , 88397 Biberach an der Riss, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm501562aDOI Listing
February 2015

Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas.

Radiother Oncol 2009 Sep 4;92(3):405-10. Epub 2009 May 4.

Department of Radiation Oncology, OncoRay Centre for Radiation Research, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse, Germany.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S016781400900161
Publisher Site
http://dx.doi.org/10.1016/j.radonc.2009.04.006DOI Listing
September 2009

CD44 suppresses TLR-mediated inflammation.

J Immunol 2008 Mar;180(6):4235-45

Department of Molecular and Tumor Pathology, Chiba University Graduate School of Medicine, Inohana, Chuo-ku, Chiba, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.180.6.4235DOI Listing
March 2008

Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells.

Int J Oncol 2007 Sep;31(3):621-6

Department of Internal Medicine-Thoracic Oncology, Clinic for Thoracic Diseases, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
September 2007

CD44 is a determinant of inflammatory bone loss.

J Exp Med 2005 Mar;201(6):903-14

Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20040852DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213110PMC
March 2005